← FDA DRUG APPROVALS
FDA ANDA · ANDA219296
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Sponsor: FOSUN WANBANG (JIANGSU) PHARMACEUTICAL GROUP CO.,
APPLICATION
ANDA219296
TYPE
ANDA
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
None (Tentative Approval)
Products
SITAGLIPTIN AND METFORMIN HYDROCHLORIDENone (Tentative Approval)
METFORMIN HYDROCHLORIDE, SITAGLIPTIN 1000MG · TABLET, EXTENDED RELEASE
SITAGLIPTIN AND METFORMIN HYDROCHLORIDENone (Tentative Approval)
METFORMIN HYDROCHLORIDE, SITAGLIPTIN 500MG · TABLET, EXTENDED RELEASE
SITAGLIPTIN AND METFORMIN HYDROCHLORIDENone (Tentative Approval)
METFORMIN HYDROCHLORIDE, SITAGLIPTIN 50MG · TABLET, EXTENDED RELEASE
SITAGLIPTIN AND METFORMIN HYDROCHLORIDENone (Tentative Approval)
METFORMIN HYDROCHLORIDE, SITAGLIPTIN EQ 100MG BASE TABLET · TABLET, EXTENDED RELEASE
Approval history
2025-08-12UNKNOWN · Original · standardTA
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.